Bal Krishna Chand Thakuri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Bal Krishna Chand Thakuri has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
Brittany Steimle
Lentigen Technology Inc., a Miltenyi Biotec Company, Gaithersburg, Maryland, USA
2 shared publications- Dina Schneider
Lentigen Technology Inc, a Miltenyi Biotec Company, Gaithersburg, MD
2 shared publications Jia-Jye Lee
Lentigen Technology Inc., a Miltenyi Biotec Company, Gaithersburg, Maryland, USA
2 shared publicationsPeirong Hu
Lentigen Technology Inc., a Miltenyi Biotec Company, Gaithersburg, Maryland, USA
2 shared publicationsSaule Nurmukhambetova
Lentigen Technology Inc., a Miltenyi Biotec Company, Gaithersburg, Maryland, USA
2 shared publications- Tri Minh Tran
Lentigen Technology Inc., a Miltenyi Biotec Company, Gaithersburg, Maryland, USA
2 shared publications
Latest Publications
- Open Access
- 12 April 2024
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 12 (4) , e008261
Armored TGFβRIIDN ROR1-CAR T cells reject solid tumors and resist suppression by constitutively-expressed and treatment-induced TGFβ1
Background: Chimeric antigen receptor (CAR) T-cell therapy target receptor tyrosine kinase-like orphan receptor 1 (ROR1) is broadly expressed in hematologic and solid tumors, however clinically-characterized ROR1-CAR T cells with single chain variable fragment (scFv)-R12 targeting domain failed to induce durable remissions, in part due to the immunosuppressive tumor microenvironment (TME). Herein, we describe the development of an improved ROR1-CAR with a novel, fully human scFv9 targeting domain, and augmented with TGFβRIIDN armor protective against a major TME factor, transforming growth factor beta (TGFβ). Methods: CAR T cells were generated by lentiviral transduction of enriched CD4+ and CD8+ T cells, and the novel scFv9-based ROR1-CAR-1 was compared with the clinically-characterized ROR1-R12-scFv-based CAR-2 in vitro and in vivo. Results: CAR-1 T cells exhibited greater CAR surface density than CAR-2 when normalized for %CAR+, and produced more interferon (IFN)-γ tumor necrosis factor (TNF)-α and interleukin (IL)-2 in response to hematologic (Jeko-1, RPMI-8226) and solid (OVCAR-3, Capan-2, NCI-H226) tumor cell lines in vitro. In vivo, CAR-1 and CAR-2 both cleared hematologic Jeko-1 lymphoma xenografts, however only CAR-1 fully rejected ovarian solid OVCAR-3 tumors, concordantly with greater expansion of CD8+ and CD4+CAR T cells, and enrichment for central and effector memory phenotype. When equipped with TGFβ-protective armor TGFβRIIDN, CAR-1 T cells resisted TGFβ-mediated pSmad2/3 phosphorylation, as compared with CAR-1 alone. When co-cultured with ROR-1+ AsPC-1 pancreatic cancer line in the presence of TGFβ1, armored CAR-1 demonstrated improved recovery of killing function, IFN-γ, TNF-α and IL-2 secretion. In mouse AsPC-1 pancreatic tumor xenografts overexpressing TGFβ1, armored CAR-1, in contrast to CAR-1 alone, achieved complete tumor remissions, and yielded accelerated expansion of CAR+ T cells, diminished circulating active TGFβ1, and no apparent toxicity or weight loss. Unexpectedly, in AsPC-1 xenografts without TGFβ overexpression, TGFβ1 production was specifically induced by ROR-1-CAR T cells interaction with ROR-1 positive tumor cells, and the TGFβRIIDN armor conferred accelerated tumor clearance. Conclusions: The novel fully human TGFßRIIDN-armored ROR1-CAR-1 T cells are highly potent against ROR1-positive tumors, and withstand the inhibitory effects of TGFß in solid TME. Moreover, TGFβ1 induction represents a novel, CAR-induced checkpoint in the solid TME, which can be circumvented by co-expressing the TGβRIIDN armor on T cells.
- 12 April 2024
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 12 (4) , e008261
Open AccessArmored TGFβRIIDN ROR1-CAR T cells reject solid tumors and resist suppression by constitutively-expressed and treatment-induced TGFβ1
Background: Chimeric antigen receptor (CAR) T-cell therapy target receptor tyrosine kinase-like orphan receptor 1 (ROR1) is broadly expressed in hematologic and solid tumors, however clinically-characterized ROR1-CAR T cells with single chain variable fragment (scFv)-R12 targeting domain failed to induce durable remissions, in part due to the immunosuppressive tumor microenvironment (TME). Herein, we describe the development of an improved ROR1-CAR with a novel, fully human scFv9 targeting domain, and augmented with TGFβRIIDN armor protective against a major TME factor, transforming growth factor beta (TGFβ). Methods: CAR T cells were generated by lentiviral transduction of enriched CD4+ and CD8+ T cells, and the novel scFv9-based ROR1-CAR-1 was compared with the clinically-characterized ROR1-R12-scFv-based CAR-2 in vitro and in vivo. Results: CAR-1 T cells exhibited greater CAR surface density than CAR-2 when normalized for %CAR+, and produced more interferon (IFN)-γ tumor necrosis factor (TNF)-α and interleukin (IL)-2 in response to hematologic (Jeko-1, RPMI-8226) and solid (OVCAR-3, Capan-2, NCI-H226) tumor cell lines in vitro. In vivo, CAR-1 and CAR-2 both cleared hematologic Jeko-1 lymphoma xenografts, however only CAR-1 fully rejected ovarian solid OVCAR-3 tumors, concordantly with greater expansion of CD8+ and CD4+CAR T cells, and enrichment for central and effector memory phenotype. When equipped with TGFβ-protective armor TGFβRIIDN, CAR-1 T cells resisted TGFβ-mediated pSmad2/3 phosphorylation, as compared with CAR-1 alone. When co-cultured with ROR-1+ AsPC-1 pancreatic cancer line in the presence of TGFβ1, armored CAR-1 demonstrated improved recovery of killing function, IFN-γ, TNF-α and IL-2 secretion. In mouse AsPC-1 pancreatic tumor xenografts overexpressing TGFβ1, armored CAR-1, in contrast to CAR-1 alone, achieved complete tumor remissions, and yielded accelerated expansion of CAR+ T cells, diminished circulating active TGFβ1, and no apparent toxicity or weight loss. Unexpectedly, in AsPC-1 xenografts without TGFβ overexpression, TGFβ1 production was specifically induced by ROR-1-CAR T cells interaction with ROR-1 positive tumor cells, and the TGFβRIIDN armor conferred accelerated tumor clearance. Conclusions: The novel fully human TGFßRIIDN-armored ROR1-CAR-1 T cells are highly potent against ROR1-positive tumors, and withstand the inhibitory effects of TGFß in solid TME. Moreover, TGFβ1 induction represents a novel, CAR-induced checkpoint in the solid TME, which can be circumvented by co-expressing the TGβRIIDN armor on T cells.
- Open Access
- 2 November 2023
- Published by BMJ
- Vol. 11 (Suppl 1) , A321
280 Multiplex immunofluorescence imaging of armored CAR T cells in pancreatic ductal adenocarcinoma mouse xenografts confirms potent anti-tumor response
Background Chimeric antigen receptor (CAR) T-cells are a promising modality for the treatment of solid tumors, however their functionality to date has been hampered by the immunosuppressive tumor microenvironment (TME). Armoring CAR T cells to overcome TME may improve clinical outcomes. We established a subcutaneous BxPC3 xenograft model of pancreatic ductal adenocarcinoma (PDAC), that exhibits hallmark characteristics of human PDAC. In this model, CAR T cells regressed tumors; by contrast, armored CAR T cells designed to resist TME, mediated an apparent tumor volume increase. We utilized MACSima™ Imaging Cycling Staining (MICS) system to elucidate the mechanism of apparent tumor volume increase post armored CAR T cell treatment, and the interactions between tumor, stroma and immune cells. Methods BxPC3 bearing NSG mice were treated with CAR T cells with or without armor, or untransduced T cell control (UTD) at high or low CAR T cell/mouse dose (2x106 or 1x106) or left untreated. FFPE sections from tumors harvested 7 days post treatment were imaged on MICS by serial immunofluorescence for 29 protein markers and nuclear stain DAPI (ROI of 3mm by 5 mm; ~14.4 mm2). Multiplex image processing and segmentation, unsupervised UMAP clustering, and target quantitation were performed on MACS® iQ view software. Results MICS of BxPC3 xenograft tissues revealed PDAC-characteristic morphology, with distinct tumor cell clusters (Pan-cytokeratin, Cytokeratin 7, MSLN, p53) and mucin vacuoles (CA125), surrounded by dense, activated stroma (Vimentin and αSMA). UMAP dimension reduction for 29 markers yielded distinct tumor and stroma clusters in each treatment group. Following CAR treatment, tumor and stroma were infiltrated by CD4+ and CD8+ human T cells. In the high CAR dose groups, there were 14.7% CD8+ tumor-infiltrating lymphocytes (TILs) in CAR alone, and 51.6% for armored CAR. Armored CAR T cells disrupted the tumor/stroma morphology and mediated a dramatic reduction in tumor cells to 1.8%, as compared to 62% for UTD control and 29.3% for CAR T alone. The armored CD8+ TILs were highly proliferative with high abundance of mitochondria: 28% of armored TILs co-expressed Ki67 and TOM22, versus 2.6% in the CAR T alone group, and 0.6% in UTD. Conclusions Using MICS technology, we therefore delineate the mechanism of action of the armored CAR-T cells in PDAC xenograft model, and rule out tumor progression. Tumor-activated armored CAR T cells manifest high proliferative and metabolic activity, superior tumor penetration and killing.
- 2 November 2023
- Published by BMJ
- Vol. 11 (Suppl 1) , A321
Open Access280 Multiplex immunofluorescence imaging of armored CAR T cells in pancreatic ductal adenocarcinoma mouse xenografts confirms potent anti-tumor response
Background Chimeric antigen receptor (CAR) T-cells are a promising modality for the treatment of solid tumors, however their functionality to date has been hampered by the immunosuppressive tumor microenvironment (TME). Armoring CAR T cells to overcome TME may improve clinical outcomes. We established a subcutaneous BxPC3 xenograft model of pancreatic ductal adenocarcinoma (PDAC), that exhibits hallmark characteristics of human PDAC. In this model, CAR T cells regressed tumors; by contrast, armored CAR T cells designed to resist TME, mediated an apparent tumor volume increase. We utilized MACSima™ Imaging Cycling Staining (MICS) system to elucidate the mechanism of apparent tumor volume increase post armored CAR T cell treatment, and the interactions between tumor, stroma and immune cells. Methods BxPC3 bearing NSG mice were treated with CAR T cells with or without armor, or untransduced T cell control (UTD) at high or low CAR T cell/mouse dose (2x106 or 1x106) or left untreated. FFPE sections from tumors harvested 7 days post treatment were imaged on MICS by serial immunofluorescence for 29 protein markers and nuclear stain DAPI (ROI of 3mm by 5 mm; ~14.4 mm2). Multiplex image processing and segmentation, unsupervised UMAP clustering, and target quantitation were performed on MACS® iQ view software. Results MICS of BxPC3 xenograft tissues revealed PDAC-characteristic morphology, with distinct tumor cell clusters (Pan-cytokeratin, Cytokeratin 7, MSLN, p53) and mucin vacuoles (CA125), surrounded by dense, activated stroma (Vimentin and αSMA). UMAP dimension reduction for 29 markers yielded distinct tumor and stroma clusters in each treatment group. Following CAR treatment, tumor and stroma were infiltrated by CD4+ and CD8+ human T cells. In the high CAR dose groups, there were 14.7% CD8+ tumor-infiltrating lymphocytes (TILs) in CAR alone, and 51.6% for armored CAR. Armored CAR T cells disrupted the tumor/stroma morphology and mediated a dramatic reduction in tumor cells to 1.8%, as compared to 62% for UTD control and 29.3% for CAR T alone. The armored CD8+ TILs were highly proliferative with high abundance of mitochondria: 28% of armored TILs co-expressed Ki67 and TOM22, versus 2.6% in the CAR T alone group, and 0.6% in UTD. Conclusions Using MICS technology, we therefore delineate the mechanism of action of the armored CAR-T cells in PDAC xenograft model, and rule out tumor progression. Tumor-activated armored CAR T cells manifest high proliferative and metabolic activity, superior tumor penetration and killing.
- 1 May 2021
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 206 (9) , 2052-2060
Long Noncoding RNA RUNXOR Promotes Myeloid-Derived Suppressor Cell Expansion and Functions via Enhancing Immunosuppressive Molecule Expressions during Latent HIV Infection
RUNX1 overlapping RNA (RUNXOR) is a long noncoding RNA and a key regulator of myeloid-derived suppressor cells (MDSCs) via targeting runt-related transcription factor 1 (RUNX1). We and others have previously reported MDSC expansion and inhibition of host immune responses during viral infections; however, the mechanisms regulating MDSC differentiation and suppressive functions, especially the role of RUNXOR-RUNX1 in the regulation of MDSCs in people living with HIV (PLHIV), remain unknown. In this study, we demonstrate that RUNXOR and RUNX1 expressions are upregulated in MDSCs that expand and accumulate in human PBMCs derived from PLHIV. We found that the upregulation of RUNXOR and RUNX1 is associated with the expressions of several key immunosuppressive molecules, including arginase 1, inducible NO synthase, STAT3, IL-6, and reactive oxygen species. RUNXOR and RUNX1 could positively regulate each other’s expression and control the expressions of these suppressive mediators. Specifically, silencing RUNXOR or RUNX1 expression in MDSCs from PLHIV attenuated MDSC expansion and immunosuppressive mediator expressions, whereas overexpressing RUNXOR in CD33+ myeloid precursors from healthy subjects promoted their differentiation into MDSCs and enhanced the expression of these mediators. Moreover, loss of RUNXOR-RUNX1 function in MDSCs improved IFN-γ production from cocultured autologous CD4 T cells derived from PLHIV. These results suggest that the RUNXOR-RUNX1 axis promotes the differentiation and suppressive functions of MDSCs via regulating multiple immunosuppressive signaling molecules and may represent a potential target for immunotherapy in conjunction with antiviral therapy in PLHIV. Key Points RUNXOR is upregulated in PLHIV to promote MDSC expansion and suppression via RUNX1. Overexpression of RUNXOR promotes MDSC expansion and suppressive functions. Silencing of RUNXOR/RUNX1 attenuates MDSC expansion and suppressive functions.
- 1 May 2021
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 206 (9) , 2052-2060
Long Noncoding RNA RUNXOR Promotes Myeloid-Derived Suppressor Cell Expansion and Functions via Enhancing Immunosuppressive Molecule Expressions during Latent HIV Infection
RUNX1 overlapping RNA (RUNXOR) is a long noncoding RNA and a key regulator of myeloid-derived suppressor cells (MDSCs) via targeting runt-related transcription factor 1 (RUNX1). We and others have previously reported MDSC expansion and inhibition of host immune responses during viral infections; however, the mechanisms regulating MDSC differentiation and suppressive functions, especially the role of RUNXOR-RUNX1 in the regulation of MDSCs in people living with HIV (PLHIV), remain unknown. In this study, we demonstrate that RUNXOR and RUNX1 expressions are upregulated in MDSCs that expand and accumulate in human PBMCs derived from PLHIV. We found that the upregulation of RUNXOR and RUNX1 is associated with the expressions of several key immunosuppressive molecules, including arginase 1, inducible NO synthase, STAT3, IL-6, and reactive oxygen species. RUNXOR and RUNX1 could positively regulate each other’s expression and control the expressions of these suppressive mediators. Specifically, silencing RUNXOR or RUNX1 expression in MDSCs from PLHIV attenuated MDSC expansion and immunosuppressive mediator expressions, whereas overexpressing RUNXOR in CD33+ myeloid precursors from healthy subjects promoted their differentiation into MDSCs and enhanced the expression of these mediators. Moreover, loss of RUNXOR-RUNX1 function in MDSCs improved IFN-γ production from cocultured autologous CD4 T cells derived from PLHIV. These results suggest that the RUNXOR-RUNX1 axis promotes the differentiation and suppressive functions of MDSCs via regulating multiple immunosuppressive signaling molecules and may represent a potential target for immunotherapy in conjunction with antiviral therapy in PLHIV. Key Points RUNXOR is upregulated in PLHIV to promote MDSC expansion and suppression via RUNX1. Overexpression of RUNXOR promotes MDSC expansion and suppressive functions. Silencing of RUNXOR/RUNX1 attenuates MDSC expansion and suppressive functions.